Effects of astragaloside IV on eosinophil activation induced by house dust mite allergen

Abstract

Abstract. Astragaloside IV (AS-IV) has been noted for its reduction of eosinophilic airway inflammation in a murine model of chronic asthma. To gain a better understanding of the mechanisms involved in this anti-inflammatory phenomenon, the effect of AS-IV on human blood eosinophils was studied in vitro. Eosinophils were isolated from the blood of patients with mild atopic asthma, preincubated with AS-IV for 1 h and stimulated in the presence or absence of the house dust mite allergen Dermatophagoides pteronyssinus (Der p) 1 for 4 h. The survival of the eosinophils at 48 h was investigated using trypan blue and the surface expression of CC chemokine receptor 3 (CCR3) and intercellular adhesion molecule-1 (ICAM-1) by the eosinophils was analyzed using flow cytometry. The secretion of cytokines in the supernatants and the chemotaxis of the eosinophils were measured by ELISA and the transwell system, respectively. Der p 1 was found to prolong the survival of the eosinophils. Similarly, the expression of CCR3 and ICAM-1, secretion of interleukin (IL)-1β, IL-5, tumor necrosis factor (TNF)-α and the granulocyte macrophage colony stimulating factor (GM-CSF) and transmigration of the eosinophils were increased in the presence of Der p 1. However, these inductive effects on the eosinophils were significantly inhibited by AS-IV (50 µg/ml). These findings suggest that AS-IV modulates eosinophil activation and trafficking in response to Der p 1 and may therefore be a useful therapeutic option in eosinophilic asthma.

Environmental assessment and exposure control of dust mites: a practice parameter

“…29 Der p 1 also can activate eosinophils to release proinflammatory mediators 324 and it can prolong their survival. 325 It has 80% homology with Der f 1. The crystal structures of natural Der p 1 and Der f 1 in complex with a monoclonal antibody, 4C1, was shown to bind to a unique cross-reactive epitope on the 2 allergens that is associated with IgE recognition.…”

The effect of astragaloside IV on JAK2‐STAT6 signalling pathway in mouse model of ovalbumin‐induced asthma

“…Besides, some studies showed AS-IV attenuates the eosinophilic infiltration in ovalbumin-induced asthma (Du et al, 2008;Gu, Jiang, Wang, Du, & Cai, 2012;Huang, Tang, Wang, & Song, 2014). Previous study used 20-40 mg/kg doses of astragaloside IV (AS-IV) daily to treat OVA-induced mouse model of asthma and had different degree levels to inhibit asthma syndrome (Jin et al, 2017).…”

Research progress on the mechanism of astragaloside IV in the treatment of asthma

“…The blockade of CCR3 has been shown to result in a reduction of eosinophilic infiltration in animal models of asthma [ 57 ]. A study has shown that astragaloside can block CCR3 [ 58 ]. We guess that the reason AS-IV can prevent the activation of the eotaxin/CCR3 signaling pathway to reduce the infiltration of eosinophils in the airway of asthmatic mice is that it downregulates the expression of CCR3 protein and reduces cytokines such as IL-4, IL-5, and IL-13 and chemokine eotaxin [ 57 , 58 ].…”